Johnson & Johnson is moving close to releasing efficacy data from Phase 3 trials of its COVID-19 vaccine candidate. Strong data and regulatory approval would represent a major step in countries’ vaccination efforts, as unlike other COVID-19 vaccines currently in use the J&J vaccine is administered as a single dose.